ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB)

– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the efficacy and safety of ADX-038 in patients with complement-mediated diseases – SAN DIEGO, Calif. ­­– November 7, 2025 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical […] The post ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB) appeared first on ADARx Pharmaceuticals .